CEPHALOTAXINE 4-METHYL (2R)-2-HYDROXY-2-(4-HYDROXY-4-METHYLPENTYL)BUTANEDIOATE (ESTER)
Acute Biphenotypic Leukemia
M.D. Anderson Cancer CenterSmall moleculePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 95/ 100
Competitive context
41 Active assets in the Acute Biphenotypic Leukemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Fludarabine Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Phase 2/3 | BB |
FILGRASTIM Ossium Health, Inc. | Phase 2 | BB |
CYTARABINE University of Washington | Phase 2 | BB |
Busulphan Ossium Health, Inc. | Phase 2 | BB |
Cyclophosphamide Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Phase 3 | BB |
View all 50 →
Same molecule, other indications
CEPHALOTAXINE 4-METHYL (2R)-2-HYDROXY-2-(4-HYDROXY-4-METHYLPENTYL)BUTANEDIOATE (ESTER) is also rated in:
acute myeloid leukemia, FLT3 internal tandem duplicationDormant
B
Indicative · Phase 2
57 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →